Lupin Limited Latest Updates

$LUPIN Sharp Net Profit Surges in Q4 FY26 Lupin Limited reported an 87.7% year-on-year jump in consolidated profit after tax (PAT) to ₹1,468.7 crore for the fourth quarter ended March 31, 2026, up from ₹782.4 crore in Q4 FY25. Total revenue from operations for the quarter expanded by 31.9% year-on-year to hit ₹7,474.7 crore compared to ₹5,667.1 crore in the corresponding block of the previous fiscal. The robust bottom-line performance was driven by operational efficiencies and key product execution in international markets. Geographically Balanced Revenue Growth United States Segment: US-based market sales led the quarterly growth engine, jumping 56.9% year-on-year to reach ₹3,398.7 crore in Q4 FY26 compared to ₹2,166.6 crore in Q4 FY25. India Formulations Segment: Domestic formulations recorded resilient steady performance, with India sales climbing 11.5% year-on-year to ₹1,908.2 crore from ₹1,711.3 crore in the corresponding quarter of the previous year. Landmark U.S. FDA Approval for Ranluspec In early June 2026, Lupin achieved a critical regulatory milestone by securing approval from the U.S. Food and Drug Administration (U.S. FDA) for Ranluspec (ranibizumab-hkdz). It is approved as an interchangeable biosimilar referencing Lucentis. Crucially, Ranluspec stands as the first and only interchangeable ranibizumab biosimilar cleared in the United States in both vials and pre-filled syringes (PFS) formats across multiple strengths to expand vision therapy access. Additional Oncology Product Nod with Natco Expanding its specialized clinical footprint, Lupin, in collaboration with Natco Pharma, received final approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection (1 mg/2 mL).